Nxera Pharma UK Limited

Nxera Pharma UK Limitied

Heptares Therapeutics Limited

Nigel Alan Swain

Miles Stuart Congreve

Giles Albert Brown

John Andrew Christopher

Benjamin Gerald Tehan

Julie Elaine Cansfield

Francesca Deflorian

Anil Patel

Stephen Paul Watson

Michael Alistair O'brien

Gregory R Ott

Anne Mary Stephenson

Mark Pickworth

Barry John Teobald

Jonathan Stephen Mason

Andrew David Cansfield

Sarah Joanne Bucknell

Mark Mills

Charlotte Fieldhouse

Geraint Jones

Andrew William Phillips

Stephen Philippe Andrews

Andrea Bortolato

Benjamin Whitehurst

Giovanni Bottegoni

The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R, R, R, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EPreceptors.

Prostaglandin EPreceptor antagonist compounds

The disclosures herein relate to novel compounds of Formula (1); and salts thereof, wherein A, A, Q, X, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

CGRP antagonist compounds

The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Orexin 1 receptor antagonists

The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Oxexin 1 receptor antagonists

Pyrazole derivatives as H4 antagonist compounds

The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

Growing community of inventors

Cambridge, United Kingdom

Nigel Alan Swain